Table 2.
Clinical, Biochemical and Angiographic Characteristics of Patients with Stable CAD in the LDL-C ≧100 mg/dL Group and LDL-C <100 mg/dL Group
| Parameters | LDL-C≧100 mg/dL (n=268) | LDL-C <100 mg/dL (n=378) | p-value |
|---|---|---|---|
| Age (years) | 62.3±10.5 | 64.5±9.7 | 0.005 |
| Male, n (%) | 175 (65.3) | 247 (65.3) | 0.990 |
| HTN, n (%) | 178 (66.5) | 239 (63.2) | 0.404 |
| DM, n (%) | 41 (15.3) | 74 (19.6) | 0.161 |
| Current smoker, n (%) | 81 (30.2) | 94 (24.9) | 0.131 |
| Family history of CAD, n (%) | 18 (6.7) | 12 (3.2) | 0.035 |
| Current drugs | |||
| ACEIs/ARBs, n (%) | 88 (32.8) | 124 (32.8) | 0.993 |
| CCBs, n (%) | 72 (26.9) | 129 (34.1) | 0.050 |
| Beta-blockers, n (%) | 16 (6.0) | 38 (10.1) | 0.065 |
| Diuretics, n (%) | 43 (16.0) | 37 (9.8) | 0.017 |
| Statins, n (%) | 7 (2.6) | 43 (11.4) | 0.000 |
| Antiplatelet drugs, n (%) | 8 (3.0) | 29 (7.7) | 0.012 |
| Triple vessel disease, n (%) | 84 (31.3) | 76 (20.1) | 0.001 |
| Syntax score ≧23, n (%) | 50 (18.7) | 50 (13.2) | 0.060 |
| Syntax score | 11 (5–19) | 9 (5–17) | 0.105 |
| SBP, mmHg | 132±18 | 129±17 | 0.036 |
| DBP, mmHg | 78±11 | 76±11 | 0.022 |
| ALB, g/L | 41.1 (38.5–43.8) | 39.8 (37.8–42.4) | 0.000 |
| ALT, U/L | 22 (15–36) | 18 (13–27) | 0.000 |
| AST, U/L | 21 (17–30) | 21 (17–26) | 0.175 |
| GGT, U/L | 30 (20–51) | 24 (17–37) | 0.000 |
| TBIL, mg/dL | 0.61 (0.42–0.82) | 0.64 (0.47–0.91) | 0.103 |
| FBG, mg/dL | 98.9 (88.5–117.9) | 94.1 (85.7–106.6) | 0.001 |
| Scr, mg/dL | 0.78 (0.67–0.93) | 0.78 (0.68–0.905) | 0.960 |
| UA, mg/dL | 6.15 (5.20–7.22) | 5.60 (4.75–6.80) | 0.000 |
| TG, mg/dL | 144.4 (103.7–204.3) | 110.8 (80.6–153.3) | 0.000 |
| TC, mg/dL | 201.0 (177.2–223.8) | 140.9 (122.4–158.1) | 0.000 |
| HDL-C, mg/dL | 44.5 (39.0–51.4) | 40.6 (34.8–48.0) | 0.000 |
| LDL-C, mg/dL | 121.0 (108.6–139.8) | 75.8 (62.1–87.8) | 0.000 |
| Lp(a), mg/dL | 16 (9–29) | 13 (7–24) | 0.003 |
| hsCRP, mg/L | 5.5 (2.6–9.1) | 2.9 (1.1–6.7) | 0.000 |
| WBC, ×103/μL | 6.4 (5.4–7.9) | 6.0 (5.0–7.3) | 0.004 |
| NEU, ×103/μL | 3.9 (3.1–4.9) | 3.7 (2.9–4.7) | 0.103 |
| LYM, ×103/μL | 1.7 (1.3–2.1) | 1.5 (1.2–2.0) | 0.001 |
| MON, ×103/μL | 0.5 (0.4–0.6) | 0.5 (0.4–0.6) | 0.377 |
| HGB, g/L | 139 (128–150) | 134 (124–145) | 0.000 |
| PLT, ×103/μL | 197 (168–236) | 183 (155–213) | 0.000 |
| MHR, ×103/mg | 11.3 (8.3–15.7) | 12.2 (8.5–16.3) | 0.159 |
| SII | 461 (315–657) | 433 (290–669) | 0.331 |
| LVEF, % | 65 (61–69) | 66 (62–71) | 0.048 |
Notes: Values are presented as means ± SD or medians (interquartile ranges) for continuous variables, and as the numbers of patients (%) for categorical variables. p-value <0.05 are presented with bold characters.
Abbreviations: Lp(a), lipoprotein(a); HTN, hypertension; DM, diabetes mellitus; CAD, coronary artery disease; ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; CCBs, calcium channel blockers; SBP, systolic blood pressure; DBP, diastolic blood pressure; ALB, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase; TBIL, total bilirubin; FBG, fasting blood glucose; Scr, serum creatinine; UA, uric acid; TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; hsCRP, high-sensitivity C-reactive protein; WBC, white blood cell; NEU, neutrophil; LYM, lymphocyte; MON, monocyte; HGB, hemoglobin; PLT, platelet; MHR, monocyte count to high-density lipoprotein cholesterol ratio; SII, systemic immune-inflammation index; LVEF, left ventricular ejection fraction.